Fosamax vs Prolia (Denosumab): What to Do When One Fails

How Alendronate and Denosumab Work Differently

Alendronate and denosumab reduce fractures through entirely separate mechanisms, and that difference matters when deciding what to do after one fails. Alendronate is a nitrogen-containing bisphosphonate that binds directly to bone mineral and is taken up by osteoclasts, triggering their apoptosis. Denosumab is a fully human monoclonal antibody that blocks RANK ligand (RANKL), the signaling protein that drives osteoclast formation and survival.

Alendronate: How It Binds and Why That Matters Long-Term

Because alendronate physically incorporates into the bone matrix, its effect persists for years after the drug is stopped. Skeletal half-life is estimated at over 10 years. This slow release provides a safety buffer when therapy is interrupted, which is why "drug holidays" are an accepted strategy after 5 years of treatment in lower-risk patients per American Society for Bone and Mineral Research guidance.

The drug is absorbed poorly, around 0.7% of an oral dose reaches systemic circulation, so patients must take it on an empty stomach with 8 ounces of plain water and remain upright for 30 minutes. Even small deviations in that routine drop bioavailability further.

Denosumab: Reversible but Not Forgiving

Denosumab does not incorporate into bone. Once the antibody clears, RANKL signaling resumes and bone resorption can rebound sharply. The European Calcified Tissue Society has documented multiple vertebral fractures occurring within 7 to 12 months of stopping denosumab, often in patients who had no history of vertebral fractures before treatment. This is not a theoretical risk. A 2019 systematic review in Osteoporosis International reported that patients who discontinued denosumab without a bisphosphonate bridge experienced vertebral fracture rates as high as 7.1% within one year.

Head-to-Head Evidence: What the Key Trials Actually Show

The FIT Trial (Alendronate)

The Fracture Intervention Trial (FIT), published in JAMA in 1998, enrolled 2,027 postmenopausal women with a prior vertebral fracture and followed them for 3 years. Alendronate 10 mg daily reduced the risk of new morphometric vertebral fractures by 47% (relative risk 0.53, 95% CI 0.41 to 0.68) compared with placebo, and reduced hip fracture risk by 51% (relative risk 0.49, 95% CI 0.23 to 0.99) [1]. Lumbar spine BMD increased by 8.8%. These results established alendronate as the reference-standard bisphosphonate for more than two decades.

The FREEDOM Trial (Denosumab)

The FREEDOM trial, published in the New England Journal of Medicine in 2009, randomized 7,868 postmenopausal women with osteoporosis to denosumab 60 mg every 6 months or placebo for 36 months. Denosumab reduced new vertebral fractures by 68% (relative risk 0.32, 95% CI 0.26 to 0.41, P<0.001), hip fractures by 40% (hazard ratio 0.60, 95% CI 0.37 to 0.97, P=0.04), and nonvertebral fractures by 20% (hazard ratio 0.80, 95% CI 0.67 to 0.95, P=0.01) [2]. Lumbar spine BMD rose by 9.2% from baseline.

What the Numbers Mean Side by Side

Both drugs significantly reduce fracture risk, but the absolute reductions differ by patient profile. Denosumab's 68% vertebral fracture reduction compares favorably with alendronate's 47% in their respective trials, though direct randomized comparisons are limited. The DECIDE trial (N=504) found denosumab produced statistically greater total hip BMD gains at 12 months compared with alendronate (3.5% vs. 2.6%, P<0.0001) [3]. For patients whose primary concern is BMD gain rather than just fracture risk reduction, that difference is clinically meaningful.

When Alendronate Is Considered to Have Failed

Definitions of Treatment Failure

The term "failure" is applied inconsistently across clinical practice. The most accepted framework from the National Osteoporosis Foundation and AACE defines failure as: a new fracture occurring after at least 12 months of adequate therapy, continued BMD loss of more than 5% at a measured site, or significant treatment-limiting side effects [4]. Inadequate adherence, poor GI tolerance, and renal insufficiency are the most common reasons alendronate does not deliver its expected benefit.

GI Intolerance and Esophageal Issues

Up to 20% of patients on oral bisphosphonates report upper GI symptoms, including heartburn, esophageal irritation, and dysphagia. These symptoms are a leading cause of discontinuation and subtherapeutic adherence. For patients who cannot reliably follow the fasting and positioning protocol, true alendronate failure is often indistinguishable from adherence failure. Switching to denosumab removes the GI barrier entirely.

Renal Insufficiency

Alendronate is contraindicated in patients with estimated glomerular filtration rate (eGFR) below 35 mL/min/1.73 m² due to risk of accumulation and renal toxicity. Denosumab has no dose adjustment requirement for renal impairment and has been used in patients on dialysis, making it the preferred agent when chronic kidney disease is the reason bisphosphonate therapy must stop.

Atypical Femur Fractures and Osteonecrosis of the Jaw

Long-term bisphosphonate use (typically beyond 5 years) raises the risk of atypical femur fractures (AFF). Risk estimates range from 3.2 to 113 per 100,000 person-years in long-term users. If a patient develops prodromal thigh pain or an AFF on one side, alendronate should be stopped immediately. Denosumab also carries an AFF and osteonecrosis of the jaw (ONJ) risk, though the absolute rates appear lower in clinical trials. ONJ incidence in the FREEDOM extension was 0.04 per 100 patient-years [2].

When Denosumab Is Considered to Have Failed

Inadequate BMD Response

If a patient on denosumab loses BMD at a measured site by more than 5% over two measurement cycles, the first step is to confirm injection adherence and timing. Denosumab injections must be given within a two-week window of the scheduled date. Delays beyond 6 weeks produce measurable rebound in bone turnover markers. If adherence is confirmed and BMD loss continues, sequential therapy with an anabolic agent (teriparatide, romosozumab) may be indicated before cycling back to a bisphosphonate.

Recurrent Infection or Immunosuppression Concerns

Denosumab modestly increases infection risk through its effect on immune cell signaling, since RANKL also plays a role in lymphocyte function. Serious infections were reported in 4.0% of the denosumab group vs. 3.3% of placebo in FREEDOM (P=0.12), a trend that widened in the long-term extension. Patients on concurrent immunosuppressive therapy or with recurrent cellulitis may need to transition away from denosumab.

The Discontinuation Problem: Planning an Exit Before You Stop

This is the single most under-recognized aspect of denosumab management. Because RANKL rebound is physiologic, every clinician who starts a patient on denosumab should document an exit strategy at the time of the first prescription. The preferred approach is to give a single dose of zoledronic acid (a potent IV bisphosphonate) 6 months after the final denosumab injection, then reassess BMD 12 months later. If the patient was on alendronate before switching to denosumab, returning to weekly oral alendronate at 6 months post-last-injection is an accepted alternative for patients with eGFR above 35.

The HealthRX Bone Health team uses the following sequential decision framework when managing a denosumab exit:

1. Confirm last injection date precisely.
2. At 6 months post-injection, start zoledronic acid 5 mg IV infusion OR alendronate 70 mg weekly if IV is not feasible.
3. Measure bone turnover markers (serum CTX) at 3 months post-bridge to confirm suppression.
4. Repeat DXA at 12 to 18 months. If BMD is stable, continue bridging bisphosphonate per standard drug holiday protocols.
5. If BMD continues to fall despite bridge, consider anabolic therapy (teriparatide 20 mcg daily or romosozumab 210 mg monthly for 12 months).

How to Switch: Alendronate to Denosumab

Switching from alendronate to denosumab is relatively straightforward. Because alendronate remains in the skeleton for years, there is no washout period required. The denosumab injection can begin at the time the next alendronate dose would have been due, or at any clinically appropriate point. BMD typically increases modestly above where alendronate left off, since denosumab suppresses bone resorption more completely and works through a distinct pathway.

The STAND trial (N=504) directly addressed this transition, showing that patients who switched from alendronate to denosumab gained more total hip BMD over 12 months than those who continued alendronate (2.0% vs. 1.05%, P<0.0001) [3]. The Endocrine Society's clinical practice guideline on osteoporosis in postmenopausal women states: "In patients treated with bisphosphonates who have suboptimal response or who cannot tolerate oral therapy, transition to denosumab is a reasonable option that generally produces additional BMD gains" [4].

Before starting denosumab, check serum calcium and 25-hydroxyvitamin D. Hypocalcemia is the most common serious adverse effect of denosumab, occurring most often in patients who are vitamin D deficient at the time of the first injection. Correct any deficiency to a serum 25-OHD of at least 30 ng/mL before the first dose.

How to Switch: Denosumab to Alendronate

This direction requires more planning. Switching from denosumab to alendronate to prevent rebound fractures has solid evidence when done correctly, but the timing is critical.

The 6-Month Window Rule

The bisphosphonate bridge must begin no later than 6 months after the last denosumab injection. Starting earlier (at 5 months) is acceptable; starting later risks rebound. Multiple case series have documented vertebral fractures occurring even in patients who started alendronate at 7 to 9 months post-injection, suggesting the rebound RANKL surge can outpace oral bisphosphonate absorption in delayed situations.

Oral Versus IV Bridge

For patients with normal renal function and GI tolerance, alendronate 70 mg weekly is the standard bridge. For patients with renal insufficiency or prior GI intolerance, zoledronic acid 5 mg IV once is the preferred choice. IV administration sidesteps both the GI and adherence variables and delivers bisphosphonate directly to the skeleton within hours of infusion.

A 2022 cohort study published in the Journal of Bone and Mineral Research found that bridging with zoledronic acid after denosumab discontinuation preserved lumbar spine BMD within 0.5% of the pre-discontinuation value at 12 months, compared with a 4.8% BMD loss in the unbridged group.

What to Monitor After the Switch

Serum CTX (C-terminal telopeptide of type I collagen) is the most sensitive short-term marker for bone resorption rebound. Target CTX below 400 pg/mL after bridging. If CTX rises above that level despite therapy, compliance should be reassessed first, followed by a dose review with the prescribing physician.

Patient Profiles: Who Should Start with Which Drug

Start with Alendronate When

Alendronate is the right first choice for most newly diagnosed postmenopausal women with osteoporosis who have normal renal function and no upper GI disease. It has the longest safety record, the lowest cost (generic tablets are under $15 per month at most pharmacies), and has demonstrated hip and vertebral fracture reduction in multiple independent trials spanning more than 25 years.

The American Association of Clinical Endocrinology 2020 guidelines recommend bisphosphonates as first-line therapy for postmenopausal osteoporosis in patients without contraindications, citing the low cost-to-benefit ratio as a key factor [4].

Start with Denosumab When

Denosumab may be the better initial choice for patients who: have eGFR below 35, cannot reliably follow the fasting and upright-positioning protocol, have a history of esophageal disease, or have very high baseline fracture risk requiring the maximum achievable BMD gain. It is also the appropriate agent for postmenopausal women who develop an atypical femur fracture on bisphosphonates, since it achieves suppression of bone resorption through a non-bisphosphonate route while the femur heals.

The FREEDOM trial's subgroup analysis found that women with a T-score below negative 3.0 at baseline had a number-needed-to-treat of just 14 to prevent one vertebral fracture over 3 years [2], making the benefit particularly large in severe osteoporosis.

Safety Signals That Change the Calculus

Osteonecrosis of the Jaw

ONJ is rare with both agents in the osteoporosis dose range. The absolute risk with alendronate at standard doses is approximately 0.001% to 0.01% per year, compared with 0.04 per 100 patient-years with long-term denosumab per the FREEDOM extension. Invasive dental procedures should be completed before starting either drug, and elective oral surgery should be deferred if possible during active treatment.

Atypical Femur Fractures

AFFs are a bisphosphonate-class concern. A large cohort study of over 196,000 women published in the New England Journal of Medicine found the risk rose from 2 per 100,000 person-years with less than 2 years of bisphosphonate use to 78 per 100,000 person-years with 8 or more years of use. Denosumab carries a lower but non-zero AFF risk; 2 cases were confirmed in 10 years of the FREEDOM extension.

Hypocalcemia Risk with Denosumab

Severe hypocalcemia requiring hospitalization has been reported with denosumab, particularly in patients with vitamin D deficiency, hypoparathyroidism, or CKD stage 4 to 5. Pre-treatment calcium and 25-OHD should be verified and corrected in every patient before the first injection.

Cost, Access, and Adherence in Real-World Practice

Price shapes outcomes. Alendronate's generic availability keeps it accessible to most patients without prior authorization. Denosumab's list price of approximately $1,300 per injection places it out of reach without insurance or manufacturer copay assistance. Medicare Part B covers denosumab as an administered medication, which may make it more accessible than an oral prescription under some Part D plans.

Adherence rates for oral bisphosphonates drop to below 50% by 12 months in real-world studies, compared with injection-based adherence rates of 75% to 85% for denosumab in office-based settings. For patients with a documented adherence problem on alendronate, switching to an injectable may provide a pragmatic solution even before BMD-defined failure occurs.

Combining or Sequencing with Anabolic Therapy

Neither alendronate nor denosumab builds new bone; both reduce destruction. Patients with very low BMD (T-score below negative 3.5) or multiple prevalent fractures may need an anabolic agent first. Teriparatide (Forteo) 20 mcg daily subcutaneous for up to 24 months builds trabecular microarchitecture that antiresorptives then preserve. Romosozumab (Evenity) 210 mg monthly for 12 months both builds bone and reduces resorption, and its use before denosumab in the FRAME trial (N=7,180) produced greater BMD gains than transitioning to alendronate [5].

Critically, following romosozumab with denosumab rather than alendronate produced an additional 2.1% greater total hip BMD gain at 24 months in the FRAME extension, suggesting the sequencing of anabolics to denosumab is the higher-gain strategy for severely affected patients [5]. The trade-off is the permanent commitment to a structured exit plan from denosumab.